In the world's fight against antibiotic resistance, Bayer CEO Marijn Dekkers sees the need for a global antibiotics bailout.» Read More
This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.
European lawmakers to debate scrapping animal testing, a move which could spell trouble for the pharma industry, experts have warned.
Britain's GlaxoSmithKline is to collaborate with U.S. scientists in developing a cure for AIDS.
A development in how patient requests for experimental drugs are handled could be a big step in health care, said a medical director Thursday.
Top-rated biotech analyst Mark Schoenebaum weighs in on latest mega-deal & bubble talk.
Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on "compassionate use" requests.
Ali Mortazavi, CEO at Silence Therapeutics, discusses the difficulties in tackling the biotech space.
Alexion has acquired Synageva Biopharma for over $8.4 billion. Ali Mortazavi, CEO at Silence Therapeutics, discusses possible reasons behind the deal.
Alexion's acquisition of Synageva is valued at $8.4 billion in cash and stock, reports CNBC's Meg Tirrell. Tom Lyndon, ETFtrends.com, discusses M&A trends in the biotech space.
GlaxoSmithKline outlined its business strategy for the next four years. Insight, with CNBC's Meg Tirrell.
IS biotech in a bubble? Mark Schoenebaum, Evercore ISI Analyst, discusses talk on Alexion to buy Synageva.
Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.
That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.
Alex Denner, Sarissa Capital Management founder, discusses the opportunity in ARIAD Pharmaceuticals.
Biotech's "great run" will continue despite a bumpy April, which came on the heels of a big jump in the sector, one analyst said.
Corey Davis, Canaccord Genuity, says Gilead's earnings put a floor in the biotech space.
Jon Najarian, co-founder of OptionMonster.com, breaks down a worrisome trend in the stock market right now.
Intarcia Therapeutics Inc. said it raised $225 million in the latest in a series of financing to support the development of its implantable drug-delivery pump for patients with diabetes.Kurt Graves, Intarcia Therapeutics chairman and CEO, discusses.
Carter Worth, head of technical analysis at Cornerstone Macro, talks U.S. stocks, including biotech, and what to expect in the month of May.
Biotech is bunking up in Cambridge's hottest zip codes as an affordable way to be in the hotbed of research. Details, with CNBC's Meg Tirrell.
Get the best of CNBC in your inbox